Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease. Although recent drugs have been approved, the complex pathophysiology of MASH limits monotherapy efficacy and generates considerable inter-patient heterogeneity. The purpose of this research was to identify new molecular targets and develop a rational combination therapeutic approach for MASH.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
